chlordiazepoxide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
diazepam derivatives	594	58-25-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: chlordiazepoxide chlordiazepoxide hydrochloride chloridazepoxide methaminodiazepoxide chlordiazepoxid chlorodiazepoxide chlordiazepoxide HCl	An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal. Molecular weight: 299.76 Formula: C16H14ClN3O CLOGP: 3.79 LIPINSKI: 0 HAC: 4 HDO: 1 TPSA: 53.14 ALOGS: -4.18 ROTB: 1 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

chlordiazepoxide
chlordiazepoxide hydrochloride
chloridazepoxide
methaminodiazepoxide
chlordiazepoxid
chlorodiazepoxide
chlordiazepoxide HCl

An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.

Molecular weight: 299.76
Formula: C16H14ClN3O
CLOGP: 3.79
LIPINSKI: 0
HAC: 4
HDO: 1
TPSA: 53.14
ALOGS: -4.18
ROTB: 1

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
30	mg	O
50	mg	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	2 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	14.30 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	99 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.25 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.37 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.06 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	8.30 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Feb. 24, 1960	FDA	VALEANT PHARM INTL

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cerebral venous thrombosis	218.08	23.17	43	3023	2031	63483925
Drug abuse	126.06	23.17	64	3002	72454	63413502
Bradyphrenia	91.80	23.17	27	3039	6953	63479003
Hyperreflexia	91.60	23.17	26	3040	5908	63480048
Thalamic infarction	81.78	23.17	15	3051	477	63485479
Drug interaction	76.42	23.17	73	2993	229058	63256898
Toxicity to various agents	69.90	23.17	72	2994	247178	63238778
Sopor	58.12	23.17	26	3040	22138	63463818
Intentional product misuse	57.28	23.17	36	3030	60881	63425075
Drug withdrawal syndrome	50.06	23.17	25	3041	27169	63458787
Disorientation	49.27	23.17	28	3038	39424	63446532
Clonus	48.33	23.17	15	3051	4621	63481335
Apraxia	47.10	23.17	12	3054	1809	63484147
Completed suicide	43.93	23.17	44	3022	145629	63340327
Perseveration	43.23	23.17	8	3058	267	63485689
Dyskinesia	38.04	23.17	22	3044	31980	63453976
Slow response to stimuli	37.83	23.17	9	3057	1023	63484933
Confusional state	37.01	23.17	51	3015	236329	63249627
Muscle twitching	33.03	23.17	17	3049	19651	63466305
Derailment	31.87	23.17	5	3061	60	63485896
Overdose	31.47	23.17	33	3033	115045	63370911
Abdominal tenderness	29.40	23.17	12	3054	8154	63477802
Abnormal behaviour	28.89	23.17	16	3050	21410	63464546
Accidental overdose	27.63	23.17	16	3050	23293	63462663
Myoclonus	27.47	23.17	14	3052	15854	63470102
Disturbance in attention	27.21	23.17	19	3047	38170	63447786
Psychomotor retardation	26.07	23.17	9	3057	3861	63482095
Cognitive disorder	24.86	23.17	21	3045	55794	63430162
Serotonin syndrome	24.57	23.17	16	3050	28666	63457290
Drug dependence	24.32	23.17	15	3051	24468	63461488

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug abuse	192.31	28.70	98	1836	98998	34855999
Toxicity to various agents	180.06	28.70	120	1814	200242	34754755
Ventricular tachyarrhythmia	103.94	28.70	18	1916	356	34954641
Delusion of replacement	61.60	28.70	10	1924	131	34954866
Shoshin beriberi	44.41	28.70	7	1927	75	34954922
Overdose	44.10	28.70	38	1896	91021	34863976
Completed suicide	37.76	28.70	36	1898	98132	34856865
Tracheobronchitis	31.54	28.70	8	1926	1033	34953964

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug abuse	300.75	22.61	156	4248	162535	79577449
Cerebral venous thrombosis	200.09	22.61	43	4361	2710	79737274
Toxicity to various agents	199.85	22.61	173	4231	421367	79318617
Hyperreflexia	83.32	22.61	27	4377	8358	79731626
Bradyphrenia	77.01	22.61	27	4377	10613	79729371
Completed suicide	74.21	22.61	79	4325	245688	79494296
Intentional product misuse	72.69	22.61	52	4352	95113	79644871
Sopor	70.37	22.61	35	4369	32975	79707009
Thalamic infarction	65.15	22.61	15	4389	1292	79738692
Delusion of replacement	59.79	22.61	10	4394	159	79739825
Drug interaction	59.30	22.61	92	4312	415091	79324893
Drug withdrawal syndrome	57.29	22.61	31	4373	34687	79705297
Disorientation	56.59	22.61	38	4366	62738	79677246
Overdose	49.93	22.61	56	4348	184150	79555834
Shoshin beriberi	44.41	22.61	7	4397	75	79739909
Clonus	40.63	22.61	15	4389	6825	79733159
Apraxia	40.11	22.61	12	4392	2855	79737129
Perseveration	39.23	22.61	8	4396	389	79739595
Cardio-respiratory arrest	38.30	22.61	38	4366	108472	79631512
Confusional state	37.88	22.61	65	4339	317932	79422052
Alcoholism	37.02	22.61	12	4392	3711	79736273
Agoraphobia	36.23	22.61	8	4396	570	79739414
Withdrawal syndrome	33.56	22.61	20	4384	26834	79713150
Accidental overdose	33.37	22.61	23	4381	39558	79700426
Abnormal behaviour	32.69	22.61	22	4382	36399	79703585
Slow response to stimuli	31.54	22.61	9	4395	1816	79738168
Delirium	30.52	22.61	30	4374	84597	79655387
Derailment	29.92	22.61	5	4399	79	79739905
Muscle twitching	29.79	22.61	18	4386	24746	79715238
Dyskinesia	28.60	22.61	22	4382	44751	79695233
Dementia	27.30	22.61	17	4387	24642	79715342
Poisoning	26.92	22.61	17	4387	25255	79714729
Tracheobronchitis	26.20	22.61	8	4396	2038	79737946
Respiratory arrest	25.74	22.61	23	4381	57527	79682457
Abdominal tenderness	24.85	22.61	12	4392	10582	79729402

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N05BA02	NERVOUS SYSTEM PSYCHOLEPTICS ANXIOLYTICS Benzodiazepine derivatives
FDA CS	M0002356	Benzodiazepines
CHEBI has role	CHEBI:35474	anti-anxiety agents
CHEBI has role	CHEBI:35717	hypnotics
CHEBI has role	CHEBI:60807	anaesthestic adjuvant
MeSH PA	D000759	Adjuvants, Anesthesia
MeSH PA	D014151	Anti-Anxiety Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D018682	GABA Agents
MeSH PA	D018757	GABA Modulators
MeSH PA	D006993	Hypnotics and Sedatives
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D014149	Tranquilizing Agents
FDA EPC	N0000175694	Benzodiazepine

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Alcohol withdrawal delirium	indication	8635005
Irritable bowel syndrome	indication	10743008	DOID:9778
Peptic ulcer	indication	13200003	DOID:750
Anxiety	indication	48694002
General anesthesia	indication	50697003
Severe anxiety (panic)	indication	80583007
Alcohol withdrawal syndrome	indication	191480000
Mixed anxiety and depressive disorder	indication	231504006
Local anesthesia	indication	386761002
Preoperative Anxiety	indication
Pre-Op Apprehension	indication
Anxiety associated with Menopause	indication
Panic disorder	off-label use	371631005	DOID:594
Tension-type headache	off-label use	398057008
Brain damage	contraindication	2470005
Hyperlipoproteinemia	contraindication	3744001	DOID:1168
Hypocalcemia	contraindication	5291005
Tachyarrhythmia	contraindication	6285003
Suicidal thoughts	contraindication	6471006
Urinary tract obstruction	contraindication	7163005	DOID:5200
Alcoholism	contraindication	7200002
Sinus tachycardia	contraindication	11092001
Hypercholesterolemia	contraindication	13644009
Severe chronic ulcerative colitis	contraindication	14311001
Disorder of lung	contraindication	19829001	DOID:850
Myocardial infarction	contraindication	22298006	DOID:5844
Glaucoma	contraindication	23986001	DOID:1686
Alcohol intoxication	contraindication	25702006
Shock	contraindication	27942005
Toxic megacolon	contraindication	28536002	DOID:1770
Orthostatic hypotension	contraindication	28651003
Atony of colon	contraindication	29479008
Torsades de pointes	contraindication	31722008
Hyperthyroidism	contraindication	34486009	DOID:7998
Depressive disorder	contraindication	35489007
Chloasma	contraindication	36209000
Migraine	contraindication	37796009	DOID:6364
Hypertensive disorder	contraindication	38341003	DOID:10763
Disorder of gallbladder	contraindication	39621005	DOID:0060262
Hypothyroidism	contraindication	40930008	DOID:1459
Complete trisomy 21 syndrome	contraindication	41040004	DOID:14250
Body fluid retention	contraindication	43498006
Hyperactive behavior	contraindication	44548000
Conduction disorder of the heart	contraindication	44808001
Achalasia of esophagus	contraindication	45564002	DOID:9164
Thrombosis of retinal vein	contraindication	46085004
Humoral hypercalcemia of malignancy	contraindication	47709007
Chronic heart failure	contraindication	48447003
Dementia	contraindication	52448006
Hepatic porphyria	contraindication	55056006	DOID:3133
Systemic lupus erythematosus	contraindication	55464009	DOID:9074
Paralytic ileus	contraindication	55525008	DOID:8442
Peptic reflux disease	contraindication	57643001
Thrombophlebitis	contraindication	64156001	DOID:3875
Ulcerative colitis	contraindication	64766004	DOID:8577
Intermenstrual bleeding - irregular	contraindication	64996003
Drug AND/OR toxin-induced diarrhea	contraindication	65979008
Substance abuse	contraindication	66214007
Psychotic disorder	contraindication	69322001
Diabetes mellitus	contraindication	73211009	DOID:9351
Sleep apnea	contraindication	73430006	DOID:0050847
Spastic paralysis	contraindication	78403003
Disturbance of salivary secretion	contraindication	78948009
Chronic idiopathic constipation	contraindication	82934008
Hiatal hernia	contraindication	84089009	DOID:12642
Open-angle glaucoma	contraindication	84494001	DOID:1067
Epilepsy	contraindication	84757009	DOID:1826
Breast lump	contraindication	89164003
Kidney disease	contraindication	90708001	DOID:557
Myasthenia gravis	contraindication	91637004	DOID:437
Uterine leiomyoma	contraindication	95315005	DOID:13223
Prolonged QT interval	contraindication	111975006
Hypoalbuminemia	contraindication	119247004
Gastrointestinal obstruction	contraindication	126765001
Deep venous thrombosis	contraindication	128053003
Endometriosis	contraindication	129103003
Autonomic dysreflexia	contraindication	129618003
Bleeding	contraindication	131148009
Mammography abnormal	contraindication	168750009
Bipolar affective disorder, current episode manic	contraindication	191618007
Asthma	contraindication	195967001	DOID:2841
Cerebrovascular accident	contraindication	230690007
Myocardial dysfunction	contraindication	233928007
Pulmonary thromboembolism	contraindication	233935004
Thrombophilia	contraindication	234467004	DOID:2452
Disease of liver	contraindication	235856003	DOID:409
Bladder outflow obstruction	contraindication	236645006
Pyloric obstruction	contraindication	244815007
Endometrial carcinoma	contraindication	254878006	DOID:2871
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Syncope	contraindication	271594007
Chorea	contraindication	271700006
Drowsy	contraindication	271782001
Pregnancy, function	contraindication	289908002
Hypertriglyceridemia	contraindication	302870006
Functional visual loss	contraindication	313165001
Severe chronic obstructive pulmonary disease	contraindication	313299006
Malignant tumor of ovary	contraindication	363443007	DOID:2394
Thromboembolic disorder	contraindication	371039008
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Cardiovascular event risk	contraindication	395112001
Gastric ulcer	contraindication	397825006	DOID:10808
Breastfeeding (mother)	contraindication	413712001
Chronic lung disease	contraindication	413839001
Disorder of coronary artery	contraindication	414024009
Obesity	contraindication	414916001	DOID:9970
Estrogen receptor positive tumor	contraindication	416053008
Myocardial infarction in recovery phase	contraindication	418044006
Porphyria	contraindication	418470004
Family history of malignant neoplasm of breast	contraindication	429740004
Congenital long QT syndrome	contraindication	442917000
Hypertensive urgency	contraindication	443482000
Carcinoma of female breast	contraindication	447782002
Smokes tobacco daily	contraindication	449868002

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.79	Basic
pKa2	4.13	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
GABA-A receptor alpha-2/beta-3/gamma-2	Ion channel	P18507 P28472 P47869	GBRG2_HUMAN GBRB3_HUMAN GBRA2_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	6.34	WOMBAT-PK	CHEMBL
GABA-A receptor alpha-3/beta-3/gamma-2	Ion channel	P18507 P28472 P34903	GBRG2_HUMAN GBRB3_HUMAN GBRA3_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	6.56	WOMBAT-PK	CHEMBL
GABA-A receptor alpha-5/beta-3/gamma-2	Ion channel	P18507 P28472 P31644	GBRG2_HUMAN GBRB3_HUMAN GBRA5_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	6.50	WOMBAT-PK	CHEMBL
GABA-A receptor alpha-1/beta-2/gamma-2	Ion channel	P14867 P18507 P47870	GBRA1_HUMAN GBRG2_HUMAN GBRB2_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	6.25	WOMBAT-PK	CHEMBL
GABA-A receptor alpha-1/beta-3/gamma-2	Ion channel	P14867 P18507 P28472	GBRA1_HUMAN GBRG2_HUMAN GBRB3_HUMAN		Ki	6.25	CHEMBL
Cholecystokinin receptor	GPCR	P32238 P32239	CCKAR_HUMAN GASR_HUMAN		IC50	4	CHEMBL
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	6.68	DRUG MATRIX
Thyrotropin-releasing hormone receptor	GPCR	P34981	TRFR_HUMAN		Ki	6.54	WOMBAT-PK
Thyrotropin-releasing hormone receptor	GPCR		TRFR_RAT	ANTAGONIST	Ki	4.82	IUPHAR
Cholinesterase	Enzyme		CHLE_HORSE		Ki	6.52	CHEMBL
Thyrotropin-releasing hormone receptor	GPCR		TRFR_MOUSE	ANTAGONIST	Ki	4.70	IUPHAR
GABA-A receptor; anion channel	Ion channel		GBRP_RAT GBRB1_RAT GBRD_RAT GBRG2_RAT GBRA5_RAT GBRA3_RAT GBRG1_RAT GBRA2_RAT GBRA4_RAT GBRG3_RAT GBRA6_RAT GBRA1_RAT GBRB3_RAT GBRB2_RAT Q91ZM7_RAT GBRE_RAT		IC50	6.70	CHEMBL
GABA-A receptor; anion channel	Ion channel		GBRA1_BOVIN GBRB1_BOVIN GBRA2_BOVIN GBRA3_BOVIN GBRA4_BOVIN GBRG2_BOVIN		IC50	6.10	CHEMBL
Cholecystokinin receptor	GPCR		CCKAR_RAT GASR_RAT		IC50	4	CHEMBL
Acetylcholinesterase	Enzyme		ACES_ELEEL		Ki	4.30	CHEMBL
Translocator protein	Membrane receptor		TSPO_RAT		Ki	6.36	CHEMBL

External reference:

ID	Source
4017780	VUID
N0000146141	NUI
D00267	KEGG_DRUG
438-41-5	SECONDARY_CAS_RN
203173	RXNORM
4017808	VANDF
C0008188	UMLSCUI
CHEBI:3611	CHEBI
CHEMBL451	ChEMBL_ID
DB00475	DRUGBANK_ID
CHEMBL1200703	ChEMBL_ID
D002707	MESH_DESCRIPTOR_UI
2712	PUBCHEM_CID
3370	IUPHAR_LIGAND_ID
1049	INN_ID
6RZ6XEZ3CR	UNII
3903	MMSL
4409	MMSL
4410	MMSL
d00189	MMSL
001454	NDDF
001455	NDDF
372866006	SNOMEDCT_US
40601003	SNOMEDCT_US
82746003	SNOMEDCT_US
4017780	VANDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Librax	HUMAN PRESCRIPTION DRUG LABEL	2	0187-4100	CAPSULE	5 mg	ORAL	NDA	18 sections
Librax	HUMAN PRESCRIPTION DRUG LABEL	2	0187-4100	CAPSULE	5 mg	ORAL	NDA	18 sections
Not applicable	HUMAN PRESCRIPTION DRUG LABEL	2	0276-0500	CAPSULE	5 mg	ORAL	ANDA	19 sections
Chlordiazepoxide and Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0378-0211	TABLET, FILM COATED	5 mg	ORAL	ANDA	25 sections
Chlordiazepoxide and Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0378-0211	TABLET, FILM COATED	5 mg	ORAL	ANDA	25 sections
Chlordiazepoxide and Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0378-0211	TABLET, FILM COATED	5 mg	ORAL	ANDA	25 sections
Chlordiazepoxide and Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0378-0277	TABLET, FILM COATED	10 mg	ORAL	ANDA	25 sections
Chlordiazepoxide and Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0378-0277	TABLET, FILM COATED	10 mg	ORAL	ANDA	25 sections
Chlordiazepoxide and Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0378-0277	TABLET, FILM COATED	10 mg	ORAL	ANDA	25 sections
Chlordiazepoxide Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0555-0033	CAPSULE	10 mg	ORAL	ANDA	18 sections
Chlordiazepoxide Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0555-0033	CAPSULE	10 mg	ORAL	ANDA	18 sections
Chlordiazepoxide Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0555-0158	CAPSULE	5 mg	ORAL	ANDA	18 sections
Chlordiazepoxide Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0555-0158	CAPSULE	5 mg	ORAL	ANDA	18 sections
Chlordiazepoxide Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0555-0159	CAPSULE	25 mg	ORAL	ANDA	18 sections
Chlordiazepoxide Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0555-0159	CAPSULE	25 mg	ORAL	ANDA	18 sections
Chlordiazepoxide Hydrochloride and Clidinium Bromide	HUMAN PRESCRIPTION DRUG LABEL	2	10135-622	CAPSULE	5 mg	ORAL	UNAPPROVED DRUG OTHER	17 sections
Chlordiazepoxide Hydrochloride and Clidinium Bromide	HUMAN PRESCRIPTION DRUG LABEL	2	11534-197	CAPSULE	5 mg	ORAL	ANDA	19 sections
Chlordiazepoxide Hydrochloride and Clidinium Bromide	HUMAN PRESCRIPTION DRUG LABEL	2	11534-197	CAPSULE	5 mg	ORAL	ANDA	19 sections
Chlordiazepoxide Hydrochloride and Clidinium Bromide	HUMAN PRESCRIPTION DRUG LABEL	2	11534-197	CAPSULE	5 mg	ORAL	ANDA	19 sections
Chlordiazepoxide Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	17856-0164	CAPSULE	25 mg	ORAL	ANDA	19 sections
chlordiazepoxide hydrochloride and clidinium bromide	HUMAN PRESCRIPTION DRUG LABEL	2	23155-808	CAPSULE	5 mg	ORAL	ANDA	19 sections
Chlordiazepoxide Hydrochloride and Clidinium Bromide	HUMAN PRESCRIPTION DRUG LABEL	2	42494-409	CAPSULE	5 mg	ORAL	NDA authorized generic	20 sections
Chlordiazepoxide and Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	42571-302	TABLET	12.50 mg	ORAL	ANDA	24 sections
Chlordiazepoxide and Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	42571-302	TABLET	12.50 mg	ORAL	ANDA	24 sections
Chlordiazepoxide and Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	42571-303	TABLET	25 mg	ORAL	ANDA	24 sections
Chlordiazepoxide and Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	42571-303	TABLET	25 mg	ORAL	ANDA	24 sections
CHLORDIAZEPOXIDE HCL AND CLIDINIUM BROMIDE	HUMAN PRESCRIPTION DRUG LABEL	2	42571-381	CAPSULE	5 mg	ORAL	ANDA	22 sections
CHLORDIAZEPOXIDE HCL AND CLIDINIUM BROMIDE	HUMAN PRESCRIPTION DRUG LABEL	2	42571-381	CAPSULE	5 mg	ORAL	ANDA	22 sections
Chlordiazepoxide Hydrochloride and Clidinium Bromide	HUMAN PRESCRIPTION DRUG LABEL	2	42582-300	CAPSULE	5 mg	ORAL	UNAPPROVED DRUG OTHER	18 sections
Chlordiazepoxide Hydrochloride and Clidinium Bromide	HUMAN PRESCRIPTION DRUG LABEL	2	42582-301	CAPSULE	5 mg	ORAL	UNAPPROVED DRUG OTHER	18 sections